Regulatory Science & Pediatric Neuro

At Imara Strategic Advisors, our work spans the full evidence lifecycle—regulatory strategy, clinical and RWE design, impact analytics, and acquisition planning. We understand that prospective partners want to see how these capabilities operate in practice. While our real client engagements are confidential, the examples below are fictionalized composites based on similar project and project components that our team has experienced in the regulatory and pediatric neurology workspace. These cases demonstrate how our evidence lifecycle can be applied to guide sponsors to timely, risk-balanced outcomes.

From 510(k) submissions to complex De Novo and PMA pathways, our regulatory case studies show how we pair deep FDA expertise with practical, data-driven strategies. These examples demonstrate how we integrate clinical trial design, RWE methodologies, and benefit–risk frameworks to guide innovators through regulatory reviews with confidence and efficiency

Regulatory Science & Evidence Strategy Case Studies

510(k) Clearance for a Remote Cardio Sensor (U.S.)

Client:

Early stage med tech building a wearable sensor to detect arrhythmias.

Pillars in Play:

Regulatory Science & Evidence Strategy; Evidence & Impact Analytics.

  • Unclear Food and Drug Administration (FDA) expectations for endpoints and predicates; limited data plan

    • Plan: Regulatory gap analysis; select a strong predicate and draft a pre‑submission (“Q‑sub”) brief.

    • Generate: Build a hybrid clinical/real‑world evidence (RWE) plan using electronic health record (EHR) signals and a small prospective study.

    • Decide: Run an internal mock review; refine benefit–risk and human factors evidence.

    • Implement: Guide labeling/claims and risk controls, align with home‑use scenarios.

    • Prove: Summarize accuracy and usability, making reviewer cross‑checks easy.

    • Scale: Create a change control playbook for future 510(k) updates.

  • 510(k) clearance; Optimized time to decision

De Novo Pathway for AI Software as a Medical Device (SaMD)

Client:

Digital health startup with machine learning ECG analysis.

Pillars in Play:

Regulatory Science & Evidence Strategy; Evidence & Impact Analytics.

  • No predicate; algorithm updates risked rereview.

    • Plan: Map to the De Novo pathway; align design with Good Machine Learning Practice (GMLP).

    • Generate: Prospective study plan with locked algorithm; bias and drift monitoring pre‑specified.

    • Decide: Develop structured documentation for cybersecurity, clinical validation, and human factors.

    • Implement: Build a change control process to manage postmarket model updates.

    • Prove: Develop clear performance summaries (sensitivity, specificity, and clinical utility).

    • Scale: Prepare templates so the granted De Novo could serve as a future predicate.

  • De Novo granted; Enables client to raise growth capital.

From Proof to Funding—Non‑Dilutive Capital for a Pediatric Device

Client:

University spin‑out developing a pediatric airway device.

Pillars in Play:

Regulatory Science & Evidence Strategy; Acquisition & Funding Strategy

  • Strong prototype, but no funding for pivotal evidence.

    • Plan: Mapped regulatory pathway (510(k) vs. De Novo) and staged study plan.

    • Generate: Drafted specific aims and evaluation plan aligned with FDA relevant endpoints.

    • Decide: Built a reviewer friendly budget and milestones; letters of support from clinical sites.

    • Implement: Submission calendar and compliance checklist; mock reviewer Q&A.

    • Prove: Evidence plan showed feasibility, patient safety, and clear decision criteria.

    • Scale: Positioned for follow‑on applications (SBIR Phase II / BARDA pediatric track, as applicable).

  • Awarding of non‑dilutive funds to execute the next phase of evidence

EU MDR RWE Strategy for a Wearable (Europe)

Client:

Mid‑size device firm renewing its CE mark under the European Union Medical Device Regulation (EU MDR)

Pillars in Play:

Regulatory Science & Evidence Strategy; Evidence & Impact Analytics

  • Underdeveloped post‑market clinical follow‑up (PMCF) plan

    • Plan: Gap analysis vs. MDR Annex XIV; clarify outcomes and safety signal thresholds.

    • Generate: Observational RWE protocol using registry + claims data; site feasibility and data use agreements.

    • Decide: Assemble PMCF plan with risk‑based surveillance triggers.

    • Implement: Set up a dashboard for adverse event trend detection.

    • Prove: Produce periodic safety update reports that match Notified Body expectations.

    • Scale: Reusable PMCF framework extended to two additional product lines

  • MDR certificate granted before MDD expiry to prevent revenue disruption and affirm distributor confidence across 18 EU markets

Pediatric Neuro & Med-Legal Consulting Case Studies

Pediatric Seizure‑Detection Wearable (Clinical + Adoption)

Client:

Early‑stage neuro‑tech company targeting pediatric epilepsy.

Pillars in Play:

Pediatric Neuro & Med‑Legal Consulting; Regulatory Science & Evidence Strategy.

  • Algorithm performance in children; clinical workflow adoption.

    • Plan: Pediatric specific endpoints and age stratified metrics; usability plan for caregivers.

    • Generate: Prospective study design with gold standard annotations; Institutional Review Board (IRB) packages.

    • Decide: Human factors validation; labeling aligned to real world use.

    • Implement: Clinic integration playbook (alerts, escalation, documentation).

    • Prove: Clear reports on positive predictive value (PPV), false alarm reduction, and caregiver training impact.

    • Scale: Case kit for payer conversations and FDA pre‑submission.

  • Improved clinical credibility; accelerated regulatory readiness and pilot adoption in pediatric epilepsy centers.

Complex Med‑Legal Causation Analysis (U.S.)

Client:

National supplier to pediatric hospitals in a multi‑party case.

Pillars in Play:

Pediatric Neuro & Med‑Legal Consulting; Evidence & Impact Analytics.

  • Determine whether neurological injury was linked to alleged prenatal events.

    • Plan: Clarify causation questions and evidentiary thresholds for court.

    • Generate: Structured review of medical records and imaging against pediatric neurology benchmarks.

    • Decide: Summarize literature on differential etiologies; prepare expert report with clear visuals.

    • Implement: Prep counsel for cross‑examination scenarios.

    • Prove: Deliver testimony using plain language and transparent methods.

    • Scale: Reusable framework for similar pediatric neurology cases.

  • PMCF plan approved without major revisions, CE Mark successfully renewed under EU MDR, and RWE framework adopted across the company’s EU portfolio, improving regulatory efficiency